Life Science Company News

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 17 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.

Under the programme initiated 6 May 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 2.2 billion in the period from 7 May 2024 to 5 August 2024.

Since the announcement 10 June 2024, the following transactions have been made:

 Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement786,545 724,234,837
10 June 202437,500985.9736,973,830
11 June 202437,000986.4936,500,308
12 June 202436,000987.4635,548,672
13 June 202436,000987.3235,543,448
14 June 202436,000986.4135,510,821
Accumulated under the programme969,045 904,311,916

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 11,068,859 B shares of DKK 0.10 as treasury shares, corresponding to 0.2% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 14 June 2024, Novo Nordisk has since 6 February 2024 repurchased a total of 9,703,295 B shares at an average share price of DKK 868.99 per B share equal to a transaction value of DKK 8,432,046,688.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
                            

Contact for further information.

Media: 
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com

 
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com

 
Investors: 
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

 
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com

 
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com

 
Sina Meyer
+45 3079 6656
azey@novonordisk.com

 
Frederik Taylor Pitter
+45 3075 8259
fptr@novonordisk.com
Ida Melvold Gjøsund
+45 3077 5649 idmg@novonordisk.com

Company announcement No 47/2024

Attachments


By: GlobeNewswire - 17 Jun 2024
Back to overview

Enhance your business development with Biotechgate